Related Experiment Videos
Concurrent linear scleroderma and systemic lupus erythematosus: a report of two cases
The Journal of Investigative Dermatology
|November 1, 1979
Summary
Two patients with linear scleroderma developed systemic lupus erythematosus, a rare association. High antibody titers initially suggested mixed connective tissue disease, but evolving symptoms confirmed SLE, highlighting anti-RNAP antibodies as potential indicators of rheumatic disease.
Area of Science:
- Rheumatology and Immunology
- Dermatology
Background:
- Linear scleroderma, also known as en coup de sabre, is a localized sclerosing skin condition.
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems.
- The co-occurrence of linear scleroderma and SLE is exceptionally rare, with limited documented cases.
Observation:
- Two patients initially diagnosed with linear scleroderma presented with evolving clinical manifestations.
- Initial serological findings included high titer antibodies to ribonucleoprotein (RNP), suggestive of mixed connective tissue disease (MCTD).
Findings:
- Both patients subsequently developed criteria for SLE, indicating a progression from localized scleroderma.
- Case 1 developed antibodies to Sm antigen, a specific marker for SLE.
- Case 2 developed antibodies to native deoxyribonucleic acid (nDNA), another hallmark of SLE.
- The presence of anti-RNAP antibodies in localized scleroderma may indicate an increased risk for developing systemic rheumatic diseases.
Implications:
- This association underscores the importance of vigilant monitoring in patients with linear scleroderma for signs of systemic autoimmune disease.
- Antibody profiling, including anti-RNP, anti-Sm, and anti-nDNA, is crucial for accurate differential diagnosis in patients with overlapping connective tissue disease features.
- Early identification of patients at risk for SLE, potentially through markers like anti-RNAP antibodies, can facilitate timely intervention and management.